Glasgow Health Solutions (GHS), headed by Dr Tom Gilhooly, has developed a blood test which detects the chemicals associated with the deterioration of nerve cells in people with MS. The blood test will track the progression of MS, allowing doctors to pinpoint when patients are about to enter the next deteriorating phase of the condition. Researchers used the test to measure the level of nitrotyrosine – the indicator of cell damage and inflammation seen in people with MS. They then used this as a biomarker for peroxynitrite activity which is thought to cause the deteriorating nerve damage in MS.